Inhibitors in haemophilia: clinical aspects.
Inhibitor development continues to be a severe complication worldwide of haemophilia therapy. Given the difficulties associated with the treatment of inhibitors in both the developed and the developing world, prediction and prevention of inhibitors following exposure to factor VIII or IX in the young child has become a management priority. Two different clinical approaches to minimizing or delaying inhibitor development are highlighted in this manuscript. Challenges in the therapy of existing inhibitors persist. However, the nature of the issues faced by physicians in the developed and developing worlds vary considerably. Both are discussed in this manuscript by representatives of both worlds, who face these challenges on a daily basis.
Dimichele
D
D
Department of Pediatrics, Weill Medical College of Cornell University, New York, NY 10021, USA. dmdimich@med.cornell.edu
Rivard
G
G
Hay
C
C
Antunes
S
S
D001779:Blood Coagulation Factors / Q000627:therapeutic use; D002648:Child; D003906:Developing Countries; D005169:Factor VIII / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000627:therapeutic use; D015942:Factor VIIa / Q000627:therapeutic use; D006467:Hemophilia A / Q000276:immunology* / Q000628:therapy; D006470:Hemorrhage / Q000517:prevention & control; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology; D011994:Recombinant Proteins / Q000627:therapeutic use; D012307:Risk Factors
D001779:Blood Coagulation Factors; D011994:Recombinant Proteins; D005169:Factor VIII; C065655:anti-inhibitor coagulant complex; D015942:Factor VIIa